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Abstract: Prior to this study, the prevalence of obstructive sleep apnoea/hypopnoea syndrome
(OSAHS) in adults with Down syndrome was unknown. We hypothesized that unrecognised
OSAHS could have an additional deleterious impact on mood and behavioural disturbances in this
group of people. Aims: To assess the prevalence of OSAHS in adults with Down syndrome in the
United Kingdom, subjectively and objectively, and ascertain its association with diurnal behavioural
disturbances. Method: Cross-sectional questionnaire study with home sleep apnoea testing (HSAT)
during 2011–2015 across the four nations of the United Kingdom. Participants were adults aged
≥16 years with Down syndrome. Main outcome measures were: self- or caregiver-completed
questionnaire data, including the Pictorial Epworth Sleepiness Scale (pESS), selected domains of the
Developmental Behavioural Checklist for Adults (DBC-A), anthropometric measures, and symptoms
of OSAHS. Objective prevalence was undertaken in a sample of responders using HSAT. Results:
Responses were received from 1321/5270 participants (25%), with 1105 valid responses (21%). Eighty-
one participants (7%) reported a prior diagnosis of OSA, of whom 38 were receiving therapy. Using
validated algorithms, a diagnosis of OSAHS was probable in 366 participants (35%), who were
younger, with higher BMI and higher mean total pESS (p < 0.0001). A total of 23% of participants had
a pESS > 10. OSAHS was a strong marker for behavioural disturbances on the DBC-A depression,
disruption and anti-social subscales (p < 0.001). Of 149 individuals who underwent HSAT, 42%
were diagnosed with OSAHS. Conclusions: Untreated OSAHS in Down syndrome is common and
associated with behavioural and mood disturbances. Improving awareness of OSAHS amongst
adults with Down syndrome, their families and healthcare professionals is essential.
Keywords: sleep-related breathing disorders; obstructive sleep apnoea; home sleep apnoea testing;
excessive daytime sleepiness; down syndrome; trisomy 21; prevalence
1. Introduction
Down syndrome, present in 1 in 1000 live births in Europe [1], is the commonest form
of intellectual disability worldwide. Currently, >37,000 people have Down syndrome in
England and Wales alone [2]. Life expectancy in people with DS is rising, and may exceed
50 years [3].
Sleep-disordered breathing is characterised by repetitive pauses in breathing during
sleep, and affects approximately 24% of the general adult population [4]. Obstructive sleep
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apnoea/hypopnoea syndrome (OSAHS) is diagnosed when nocturnal apnoea results in
significant diurnal symptoms, including excessive daytime somnolence, impaired cognitive
function, reduced quality of life, and behavioural and emotional disturbances [4]. The
adult prevalence of OSAHS is 2% in women and 4% in men [4]. OSAHS is an independent
risk factor for cardiovascular morbidity and mortality, including hypertension, myocardial
infarction and stroke [4].
The Down syndrome phenotype includes a flattened face, short neck, generalised
hypotonia, loose ligaments, and a tendency towards weight gain—all risk factors for
OSAHS. The additional impact of OSAHS on cognitive ability in DS is still unknown, but
may have additional deleterious effects [5].
OSAHS prevalence in children with Down syndrome has been reported to be ap-
proximately 45–55% [6]; the prevalence in adults with Down syndrome was unknown.
Two small studies in adults with Down syndrome (n = 6; n = 16) reported >80% of their
respective samples to have obstructive sleep apnoea, but these studies may not be represen-
tative of the wider Down syndrome population [7,8]. A questionnaire study in Canada [9]
reported a diagnosis of OSA in 21% of 223 individuals with Down syndrome aged 1 month
to >40 years, but prevalence data for adults only were not reported.
The aim of this study was to establish the prevalence and severity of symptoms
of OSAHS and related behavioural and emotional disturbances in adults with Down
syndrome using subjective and objective measures. We hypothesised that OSAHS would
be a strong marker for diurnal behavioural disturbances in adults with Down syndrome.
2. Methods
2.1. Study Design and Data
The study was approved by the Scotland A Research Ethics Committee (REC no:
11/MRE00/3). Return of a completed questionnaire was considered implicit consent to par-
ticipate. Individuals undertaking home sleep apnoea testing gave written informed consent.
2.2. Subjective Prevalence
Questionnaires and pre-paid reply envelopes were sent to 5266 UK-based adults
(≥16 years) with Down syndrome and their caregivers between 2011 and 2014. Potential
study participants were identified by local and national organisations supporting people
with Down syndrome (see Acknowledgements).
The questionnaire comprised a section for completion by the individual with Down
syndrome and a section for completion by a relative/caregiver. Anthropometric, comor-
bidity, medication, demographic, and sleep disturbance data (including frequency per
week of snoring, witnessed apnoeas, nocturnal choking episodes, frequent awakenings,
unrefreshing sleep, and daytime sleepiness) were collected. The pictorial version of the
Epworth Sleepiness Scale (pESS) [10], designed to enhance understanding and accessibility
in a broader adult population, was also administered. Prior to this study, the pESS had not
been used in a population with Down syndrome.
Additionally, caregivers completed three subscales of the Developmental Behaviour
Checklist for Adults (DBC-A) [11], which may be related to sleep deprivation: Disruptive,
Anxiety/Antisocial, and Depressive. Subscales were scored as described by Taffe et al. [12].
The DBC-A has been used extensively in populations with people with Down syndrome.
Medications were classified using the World Health Organisation Anatomical Thera-
peutic Chemical Classification System [13].
Reported symptoms suggestive of OSAHS were defined using three previously vali-
dated algorithms: [14]
1. Snoring ≥ 3 nights/week plus (witnessed apnoeas, or pESS > 10).
2. Snoring≥ 3 nights/week plus (witnessed apnoeas, or unrefreshing sleep≥ 3 nights/week).
3. Snoring ≥ 3 nights/week plus (witnessed apnoeas, or daytime sleepiness ≥ 3/week).
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2.3. Objective Prevalence
In order to assess objective prevalence of OSAHS by sampling as true a cross-section
of the target population as possible, responders were considered eligible if aged ≥16 years
with Down syndrome and not currently using CPAP; home sleep apnoea testing was
offered regardless of subjective sleepiness, sleep-related symptoms, previous sleep diag-
noses or any other variables reported in the questionnaire and first recruitment occurred
10 January 2012.
Home sleep studies were conducted using the Embletta® Gold™ (Embla Systems
LLC., Amsterdam, The Netherlands) cardiorespiratory polygraphy device. This is a level
III device [15], with the capacity to record multiple channels of physiological data. Home
sleep apnoea testing by level III polygraphy is routinely used in clinical practice across the
UK. Channels were recorded in broad accordance with AASM guidelines for full PSG [16],
as recommended by the AASM guidelines for portable monitoring [15], and included
nasal airflow and snoring via nasal pressure cannula, respiratory effort via thoracic and
abdominal respiratory inductance plethysmography bands, SpO2 via pulse oximetry and
body position via an inbuilt position sensor.
All studies were manually validated and scored by one of two experienced Registered
Polysomnographic Technologists using standard software (Embla® RemLogic™ Embla
Systems LLC., Amsterdam, The Netherlands) in broad accordance with current interna-
tional guidelines [16]. To ensure consistency of scoring, inter- and intra-rater reliability
scoring was conducted in randomly selected subsets of 10% of valid studies.
2.4. Statistical Analysis
Standard statistical analyses were undertaken using IBM SPSS Statistics for Windows
Version 19.0 (IBM Corp., Armonk, NY, USA).
All variables were checked for normality. Descriptive statistics were generated to
report frequencies of sleep problems and participant characteristics. The chi-square test was
used for discrete variables, Student’s t-test for continuous variables, and Mann–Whitney U
test for non-parametric data, to investigate anthropometric, sleep, and behavioural and
emotional associations with probable OSA, and gender differences in sleep and behavioural
and emotional characteristics. A conservative cut-off for significance was taken at p < 0.001
to account for the effects of multiple testing (with alpha = 0.004 to 0.0025 depending on
the number of variables). Though a little stringent, we believed that this would lead to
mitigating Type I error further in a sample of this size without having to undertake a Bon-
ferroni or Holm correction on each occasion. Pearson’s and Spearman’s rank correlations
were used to examine possible associations between anthropometrics, sleep characteristics
and behavioural and emotional disturbances. Both binary logistic regression analysis (for
exploring a pESS cut-off score below and above 10/24) and generalised linear modelling
were undertaken to explore independent associations of OSAHS with anthropometric
characteristics, medication use and behaviour/emotion. All analyses were two-tailed.
Results are presented as mean ± standard deviation for parametric variables or
median with interquartile range (IQR 25 to 75%) for non-parametric data, or as number
and percentage.
2.5. Role of Funding Bodies and Study Sponsors
The Chief Scientist Office (Edinburgh, UK), Baily Thomas Charitable Trust (Luton,
UK) and Fondation Jérôme Lejeune (Paris, France) funded this study. ResMed (UK) Ltd.
provided non-financial support via loan of home sleep study equipment. None of these
parties were actively involved in the design, analysis or reporting of the study. As study
sponsors, Lothian Universities Health Trust and the University of Edinburgh did not play
any role in the planning, conducting or analysis of this study.
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2.6. Public and Patient Involvement
Adults with Down syndrome reviewed the study materials for accessibility via focus
groups organised through Down’s Syndrome Scotland, a national organisation supporting
people with Down syndrome and their families, with amendments made in line with
feedback received.
3. Results
Responses were received from 1321/5270 participants (25%), of which 1105 responses
(21%) were valid for analysis (Figure 1).
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All Responders Male Female 
p ** 
n = 1067 n = 585 (54.8%) * n = 480 (45.0%) * 
Age (years) 1062 28 ± 9 28 ± 9 28 ± 9 0.99 
Body Mass Index (kg/m2) *** 911 29.0 ± 6.8 28.2 ± 6.6 30.0 ± 6.8 <0.0001 
Underweight (<18.5 kg/m2) 
744 
6 0.8% 3 0.7% 3 0.9% 
0.001 
Normal weight (18.5–24.99 kg/m2) 187 25.1% 124 30.1% 63 19.0% 
Pre-obesity (25.0–29.99 kg/m2) 255 34.3% 147 35.7% 107 32.3% 
Obesity class I (30.0–34.99 kg/m2) 154 20.7% 74 18.0% 80 24.2% 
Obesity class II (35.0–39.99 kg/m2) 91 12.2% 43 10.4% 48 14.5% 
Obesity class III (≥40.00 kg/m2) 51 6.9% 21 5.1% 30 9.1% 
Collar size (cm) 579 40.4 ± 4.3 41.3 ± 3.8 38.2 ± 4.5 <0.0001 
Smoking status: 
Smoker 1017 1 0.1% 1 0.2% 0 0.0% 0.54 
Figure 1. Summary of questionnaires distributed to adults with Down syndrome residing within the
UK, returned to the investigators and included in the final analysis.
Fifty-three men and 28 women (7%) reported a prior diagnosis of OSA. Of these, 38
(3.4% of the total) were receiving continuous positive airway pressure (CPAP) therapy
and were excluded from further analysis. Other reported sleep disorders included insom-
nia (n = 2), narcolepsy (n = 1), behavioural sleep problems (n = 1), parasomnia (n = 1),
headbanging (n = 1), myoclonic jerks (n = 1), nightmares (n = 1) and somniloquy (n = 1).
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3.1. Anthropometric Data and Comorbidities
Anthropometric characteristics of the responders included in the study are shown in
Table 1. Most participants were overweight (34%) or obese (40%) [17].
Table 1. Anthropometric characteristics of all valid questionnaire responders, with responders on CPAP therapy excluded.
Chi-square test used for parametric categorical variables, t-test for continuous categorical variables and Mann–Whitney




All Responders Male Female p **n = 1067 n = 585 (54.8%) * n = 480 (45.0%) *
Age (years) 1062 28 ± 9 28 ± 9 28 ± 9 0.99
Body Mass Index (kg/m2) *** 911 29.0 ± 6.8 28.2 ± 6.6 30.0 ± 6.8 <0.0001
Underweight (<18.5 kg/m2)
744
6 0.8% 3 0.7% 3 0.9%
0.001
Normal weight (18.5–24.99 kg/m2) 187 25.1% 124 30.1% 63 19.0%
Pre-obesity (25.0–29.99 kg/m2) 255 34.3% 147 35.7% 107 32.3%
Obesity class I (30.0–34.99 kg/m2) 154 20.7% 74 18.0% 80 24.2%
Obesity class II (35.0–39.99 kg/m2) 91 12.2% 43 10.4% 48 14.5%
Obesity class III (≥40.00 kg/m2) 51 6.9% 21 5.1% 30 9.1%




1 0.1% 1 0.2% 0 0.0%
0.54Ex-smoker 5 0.5% 2 0.4% 3 0.6%
Non-smoker 1011 99.4% 548 99.5% 462 99.4%
Any medication 1067 728 68.2% 369 63.1% 359 74.8% <0.0001
Comorbidities:
Asthma 1067 135 12.7% 75 12.8% 60 12.5% 0.93
Adenoid and/or tonsil surgery 1067 249 23.3% 136 23.2% 113 23.5% 0.94
Stroke 1067 16 1.5% 7 1.2% 9 1.9% 0.45
Broken nose 1067 8 0.7% 6 1.0% 2 0.4% 0.31
Diabetes 1067 29 2.7% 13 2.2% 16 3.3% 0.34
Heart problems 1067 37.2 3.5% 182 31.1% 215 44.8% <0.0001
Hay fever 1067 193 18.1% 104 17.8% 89 18.5% 0.75
Thyroid problems 1067 379 35.5% 168 28.7% 210 43.8% <0.0001
Epilepsy 1067 62 5.8% 31 5.3% 31 6.5% 0.43
Liver problems 1067 17 1.6% 13 2.2% 4 0.8% 0.09
Hypertension 1067 19 1.8% 9 1.5% 10 2.1% 0.64
Nasal surgery 1067 15 1.4% 8 1.4% 7 1.5% 1.00
Kidney problems 1067 23 2.2% 11 1.9% 12 2.5% 0.53
Gluten intolerance 1067 61 5.7% 26 4.4% 35 7.3% 0.06
* Gender of 2 responders unknown; ** Difference between males and females; *** WHO BMI category calculated for participants aged
≥20 years only.
Females had a significantly higher body mass index than males (males 28.2 ± 6.6 kg/m2,
females 30.0 ± 6.8 kg/m2; p < 0.0001), but smaller collar size (males 41.3 ± 3.8 cm, females
38.2 ± 4.5 cm; p < 0.0001). No other significant gender differences were observed.
The prevalence of comorbidities that can be related to OSAHS or potentially affecting
sleep (Table 1) was low: hay fever (18%); asthma (13%); epilepsy (6%); diabetes (3%);
hypertension (2%); stroke (2%).
Adenotonsillar hypertrophy is known to affect upper airway size and function in both
adults and children in the general population. A total of 243 responders (23%) reported
removal of tonsils and/or adenoids and 124 (12%) reported adenotonsillectomy. There
was a trend for those who had undergone surgery to be more likely to meet the criteria for
probable OSAHS (42% vs. 32%, p = 0.002; data not shown).
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3.2. Sleep Symptoms
Probable OSAHS criteria [16] were met by 366 participants (35%), who were signifi-
cantly younger, with higher body mass index, higher mean total pESS and more likely to
have a pESS > 10 (all p < 0.0001) (Tables 2 and 3 online). Mean pESS scores were within
the normal range (7 ± 5), with no significant gender difference (Table 4 online). Excessive
daytime somnolence (pESS > 10) was classified in 23% of participants, with no significant
gender difference.
Table 2. Sleep and behaviour characteristics of responders meeting criteria for probable OSA on ≥1 algorithm, with
responders on CPAP therapy excluded. Chi-square test used for parametric categorical variables, t-test for continuous
categorical variables and Mann–Whitney U test for non-parametric variables. Values presented as mean ± SD, median
(IQR) or n % unless otherwise stated.
Characteristics Total Responses
Probable OSA OSA Not Suspected p
n = 366 (34.3%) * n = 673 (63.1%) *
Prior diagnosis of obstructive sleep apnoea (OSA) 1039 31 8.5% 13 1.9% <0.0001
DBC-A Disruptive subscale (scale range 0–34) 1023 7 (3–12) 4 (1–8) <0.0001
Mean item score (possible score 0–2) 1023 0.42 (0.18–0.71) 0.24 (0.06–0.50) <0.0001
Proportion of items checked (possible score 0–1) 1023 0.41 (0.18–0.59) 0.24 (0.06–0.41) <0.0001
Intensity index (possible score 0–1) 895 0.10 (0.00–0.33) 0.00 (0.00–0.22) <0.0001
DBC-A Anxiety/Antisocial subscale (scale range −2–14) 1021 0 (−1–2) 0 (0–1) 0.047
Mean item score (possible score 0–2) 1021 0.22 (0.11–0.44) 0.11 (0.00–0.33) <0.0001
Proportion of items checked (possible score 0–1) 1021 0.22 (0.11–0.33) 0.11 (0.00–0.22) <0.0001
Intensity index (possible score 0–1) 766 0.25 (0.00–0.50) 0.00 (0.00–0.50) 0.001
DBC-A Depressive subscale (scale range 0–18) 1024 3 (1–6) 1 (0–4) <0.0001
Mean item score (possible score 0–2) 1024 0.33 (0.11–0.67) 0.11 (0.00–0.44) <0.0001
Proportion of items checked (possible score 0–1) 1024 0.33 (0.11–0.56) 0.11 (0.00–0.33) <0.0001
Intensity index (possible score 0–1) 718 0.00 (0.00–0.39) 0.00 (0.00–0.25) 0.002
Pictorial Epworth Sleepiness Scale (pESS) 933 9 ± 6 6 ± 5 <0.0001
Pictorial Epworth Sleepiness Scale score >10 933 126 38.8% 89 14.6% <0.0001
Estimated total sleep time (TST) in 24 h (h) 545 9.2 ± 1.5 9.0 ± 1.3 0.10
Estimated TST during night (h) 988 8.5 ± 1.3 8.7 ± 1.2 0.02
Estimated TST during daytime (h) 834 0.0 (0.0–0.1) 0.0 (0.0–0.0) <0.0001
Naps in daytime 812 111 40.8% 123 22.8% <0.0001
Snoring—ever (≥1 night/week)
1038
366 100.0% 450 67.0% -
Never 0 0.0% 149 22.2%
<0.0001Rarely/sometimes (1–2 night/week) 0 0.0% 396 58.9%
Often/frequent (≥3 nights/week) 366 100.0% 54 8.0%
Don’t know 0 0.0% 73 10.9% -
Witnessed apnoeas—ever (≥1 night/week)
1017
206 56.9% 103 15.7% -
Never 20 5.5% 339 51.8%
<0.0001Rarely/sometimes (1–2 night/week) 82 22.7% 78 11.9%
Often/frequent (≥3 nights/week) 124 34.3% 25 3.8%
Don’t know 136 37.6% 213 32.5% -
Nocturnal choking episodes—ever (≥1 night/week)
1021
160 44.9% 117 17.6% -
Never 145 40.7% 495 74.4%
<0.0001Rarely/sometimes (1–2 night/week) 111 31.2% 105 15.8%
Often/frequent (≥3 nights/week) 49 13.8% 12 1.8%
Don’t know 51 14.3% 53 8.0% -
Frequent night awakenings—ever (≥1 night/week)
1021
292 81.1% 434 65.7% -
Never 36 10.0% 195 29.5%
<0.0001Rarely/sometimes (1–2 night/week) 158 43.9% 316 47.8%
Often/frequent (≥3 nights/week) 134 37.2% 118 17.9%
Don’t know 32 8.9% 32 4.8% -
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Table 2. Cont.
Characteristics Total Responses
Probable OSA OSA Not Suspected p
n = 366 (34.3%) * n = 673 (63.1%) *
Unrefreshing sleep—ever (≥1 night/week)
1027
313 86.2% 431 64.9% -
Never 18 5.0% 188 28.3%
<0.0001Rarely/sometimes (1–2 night/week) 118 32.5% 299 45.0%
Often/frequent (≥3 nights/week) 195 53.7% 132 19.9%
Don’t know 32 8.8% 45 6.8% -
Daytime sleepiness—ever (≥1 night/week)
1029
322 88.7% 448 67.3% -
Never 36 9.9% 205 30.8%
<0.0001Rarely/sometimes (1–2 night/week) 150 41.3% 335 50.3%
Often/frequent (≥3 nights/week) 172 47.4% 113 17.0%
Don’t know 5 1.4% 13 2.0% -
* OSA probability could not be calculated for 28 responders (2.6%).
Table 3. Anthropometric characteristics of responders meeting criteria for probable OSA on ≥1 algorithm, with responders
on CPAP therapy excluded. Chi-square test used for parametric categorical variables, t-test for continuous categori-
cal variables and Mann–Whitney U test for non-parametric variables. Values presented as mean ± SD or n % unless
otherwise stated.
Characteristics Total Responses
Probable OSA OSA Not Suspected p
n = 366 (34.3%) * n = 673 (63.1%) *
Age (years) 1004 26 ± 8 29 ± 10 <0.0001
Gender (males:females) 1037 206:159 363:309 0.47
Collar size (cm) 565 41 ± 4.6 40.1 ± 4.0 0.02
Body Mass Index (kg/m2) ** 884 30.0 ± 1.3 27.4 ± 1.2 <0.0001
Underweight (<18.5 kg/m2)
721
0 0.0% 6 1.3%
<0.0001
Normal weight (18.5–24.99 kg/m2) 42 17.3% 140 29.3%
Pre-obesity (25.0–29.99 kg/m2) 81 33.3% 168 35.1%
Obesity class I (30.0–34.99 kg/m2) 48 19.8% 100 20.9%
Obesity class II (35.0–39.99 kg/m2) 44 18.1% 42 8.8%
Obesity class III (≥40.00 kg/m2) 28 11.5% 22 4.6%
Any medication 1039 273 74.6% 473 70.3% 0.001
Benzodiazepines/Z-drugs 1039 7 1.9% 6 0.9% 0.24
Opiates 1039 6 1.6% 6 0.9% 0.36
Antidepressants 1039 21 5.7% 33 4.9% 0.56
Antiepileptics 1039 24 6.6% 19 2.8% 0.005
Antihistamines 1039 35 9.6% 36 5.3% 0.01
Contraceptives 1039 29 7.9% 33 4.9% 0.06
Melatonin 1039 7 1.9% 9 1.3% 0.60
Oxygen 1039 4 1.1% 6 0.9% 0.75
Comorbidities:
Asthma 1039 64 17.5% 68 10.1% 0.001
Stroke 1039 1 0.3% 14 2.1% 0.03
Broken nose 1039 1 0.3% 6 0.9% 0.43
Diabetes 1039 7 1.9% 20 3.0% 0.42
Heart problems 1039 152 41.5% 231 34.3% 0.02
Hay fever 1039 79 21.6% 111 16.5% 0.04
Thyroid problems 1039 130 35.5% 242 36.0% 0.95
Epilepsy 1039 35 9.6% 25 3.7% <0.0001
Liver 1039 2 0.5% 13 1.9% 0.10
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Table 3. Cont.
Characteristics Total Responses
Probable OSA OSA Not Suspected p
n = 366 (34.3%) * n = 673 (63.1%) *
Hypertension 1039 10 2.7% 8 1.2% 0.08
Nasal surgery 1039 6 1.6% 8 1.2% 0.58
Kidney problems 1039 13 3.6% 9 1.3% 0.02
Gluten intolerance 1039 20 5.5% 39 5.8% 0.89
Any adenoid and/or tonsil surgery 1039 105 28.7% 135 20.1% 0.002
* OSA probability could not be calculated for 28 responders (2.6%); ** WHO BMI category calculated for participants aged ≥20 years only.
Table 4. Self-reported sleep and behaviour characteristics of valid questionnaire responders, with responders on CPAP
therapy excluded. Chi-square test used for parametric categorical variables, t-test for continuous categorical variables
and Mann–Whitney U test for non-parametric variables. Values presented as mean ± SD, median (IQR) or n % unless
otherwise stated.
Sleep and Behaviour Characteristics TotalResponses
All Responders Male Female p **n = 1067 n = 585 (54.8%) * n = 480 (45.0%) *
Developmental Behaviour Checklist for Adults (DBC-A):
Disruptive behaviour subscale (scale range 0–34) 1050 5 (2 to 10) 4 (2 to 9) 6 (2 to 11) 0.003
Mean item score (possible score 0–2) 1050 0.29 (0.12 to 0.59) 0.27 (0.12 to 0.55) 0.35 (0.16 to 0.65) 0.002
Proportion of items checked (possible score 0–1) 1050 0.29 (0.12 to 0.53) 0.24 (0.12 to 0.47) 0.29 (0.12 to 0.53) 0.001
Intensity index (possible score 0–1) 920 0.00 (0.00 to 0.27) 0.00 (0.00 to 0.29) 0.00 (0.00 to 0.27) 0.55
Anxiety/Antisocial subscale (scale range −2–14) 1035 0 (0 to 1) 0 (0 to 1) 0 (−1 to 1) 0.96
Mean item score (possible score 0–2) 1035 0.22 (0.00 to 0.33) 0.22 (0.00 to 0.33) 0.22 (0.11 to 0.33) 0.66
Proportion of items checked (possible score 0–1) 1035 0.11 (0.00 to 0.33) 0.11 (0.00 to 0.33) 0.11 (0.11 to 0.33) 0.64
Intensity index (possible score 0–1) 783 0.00 (0.00 to 0.50) 0.00 (0.00 to 0.50) 0.00 (0.00 to 0.50) 0.91
Depressive subscale (scale range 0–18) 1050 2 (0 to 5) 2 (0 to 5) 2 (0 to 5) 0.17
Mean item score (possible score 0–2) 1050 0.22 (0.00 to 0.56) 0.22 (0.00 to 0.56) 0.22 (0.00 to 0.56) 0.04
Proportion of items checked (possible score 0–1) 1050 0.22 (0.00 to 0.44) 0.22 (0.00 to 0.44) 0.22 (0.00 to 0.44) 0.03
Intensity index (possible score 0–1) 735 0.00 (0.00 to 0.33) 0.00 (0.00 to 0.33) 0.00 (0.00 to 0.33) 0.99
Pictorial Epworth Sleepiness Scale (pESS) 954 7 ± 5 7 ± 6 7 ± 5 0.02
Pictorial Epworth Sleepiness Scale score >10 954 215 22.5% 124 23.8% 90 20.9% 0.31
Estimated total sleep time (TST) in 24 h (h) 559 9.1 ± 1.3 8.9 ± 1.4 9.2 ± 1.3 0.004
Estimated TST during night (h) 1011 8.6 ± 1.2 8.5 ± 1.3 8.8 ± 1.2 <0.0001
Estimated TST during daytime (h) 834 0 (0 to 0.5) 0 (0 to 0.5) 0 (0 to 0.5) 0.96
Naps in daytime 834 235 28.2% 125 27.9% 109 28.3% 0.94
Snoring—ever (≥1 night/week)
1052
830 78.9% 462 80.1% 366 77.4% -
Never 149 14.2% 75 13.0% 74 15.6%
0.41Rarely/sometimes (1–2 night/week) 396 37.6% 224 38.8% 171 36.2%
Often/frequent (≥3 nights/week) 434 41.3% 238 41.2% 195 41.2%
Don’t know 73 6.9% 40 6.9% 33 7.0% -
Witnessed apnoeas—ever (≥1 night/week)
1029
309 30.0% 175 30.8% 133 29.0% -
Never 370 36.0% 200 35.2% 169 36.8%
0.19Rarely/sometimes (1–2 night/week) 160 15.5% 83 14.6% 76 16.6%
Often/frequent (≥3 nights/week) 149 14.5% 92 16.2% 57 12.4%
Don’t know 350 34.0% 193 34.0% 157 34.2% -
Nocturnal choking episodes—ever (≥1 night/week)
1042
282 27.1% 142 24.9% 140 29.9% -
Never 656 63.0% 362 63.4% 292 62.3%
0.37Rarely/sometimes (1–2 night/week) 221 21.2% 111 19.4% 110 23.5%
Often/frequent (≥3 nights/week) 61 5.9% 31 5.4% 30 6.4%
Don’t know 104 10.0% 67 11.7% 37 7.9% -
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Table 4. Cont.
Sleep and Behaviour Characteristics TotalResponses
All Responders Male Female p **n = 1067 n = 585 (54.8%) * n = 480 (45.0%) *
Frequent night awakenings—ever (≥1 night/week)
1044
743 71.2% 393 68.7% 349 74.3% -
Never 237 22.7% 235 41.1% 101 21.5%
0.36Rarely/sometimes (1–2 night/week) 484 46.4% 262 45.8% 222 47.2%
Often/frequent (≥3 nights/week) 259 24.8% 131 22.9% 127 27.0%
Don’t know 64 6.1% 44 7.7% 20 4.3% -
Unrefreshing sleep—ever (≥1 night/week)
1047
760 72.6% 413 72.3% 470 73.0% -
Never 210 20.1% 114 20.0% 95 20.0%
0.90Rarely/sometimes (1–2 night/week) 428 40.9% 236 41.3% 192 40.5%
Often/frequent (≥3 nights/week) 332 31.7% 177 31.0% 154 32.5%
Don’t know 77 7.4% 44 7.7% 33 7.0% -
Daytime sleepiness—ever (≥1 night/week)
1050
787 75.0% 443 93.1% 342 72.5% -
Never 244 23.2% 121 25.4% 123 26.1%
0.11Rarely/sometimes (1–2 night/week) 500 47.6% 276 58.0% 224 47.5%
Often/frequent (≥3 nights/week) 287 27.3% 167 35.1% 118 25.0%
Don’t know 19 1.8% 12 2.5% 7 1.5% -
Obstructive sleep apnoea (OSA) status:
Prior diagnosis of OSA 1067 44 4.1% 29 5.0% 15 3.1% 0.16
Probable OSA using definition 1 1038 350 33.7% 199 34.9% 150 32.2% 0.39
Probable OSA using definition 2 1042 356 34.2% 200 35.1% 155 33.0% 0.51
Probable OSA using definition 3 1038 352 33.9% 200 35.1% 151 32.4% 0.39
Probable OSA on ≥1 definition 1039 366 35.2% 206 36.2% 159 34.0% 0.47
* Gender of 2 responders unknown; ** Difference between males and females.
The mean self-reported total sleep time was 9.1 ± 1.3 h in 24 h, with 8.6 ± 1.2 h of
nocturnal sleep. Most participants (72%) did not take daytime naps. Nocturnal total sleep
time was significantly higher in females (<0.0001).
3.3. Behavioural and Emotional Disturbances
As hypothesised, OSAHS was a strong marker for diurnal behavioural disturbances;
individuals with probable OSAHS scored significantly higher on all three DBC-A domains
(Table 2). Independent determinants of sleepiness and behavioural and emotional dis-
turbances are summarised in Tables 5 and 6, and include use of category N medications,
unrefreshing sleep and frequent nocturnal awakenings.
Table 5. Determinants of sleepiness and probable obstructive sleep apnoea/hypopnoea syndrome as assessed by binary
logistic regression (OR) * or generalised linear modelling (β) ** as appropriate for categorical and continuous variables,
respectively. DBC-A Disruptive subscale analysed separately for males and females due to significant difference in scores
at baseline.
Variable Total Included Determinants Remaining in Model Estimate 95% CI Lower 95% CI Upper p
Pictorial Epworth
Sleepiness Scale **
Age 0.0 0.0 0.1 0.07
BMI 0.1 0.0 0.2 0.004
Hay fever 1.3 0.2 2.4 0.02
Category G medication 2.2 0.5 3.9 0.01




1.8 0.8 2.8 0.001
Witnessed apnoeas—often/frequently
(≥3 nights/week) 5.5 4.4 6.6 <0.0001
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Table 5. Cont.
Variable Total Included Determinants Remaining in Model Estimate 95% CI Lower 95% CI Upper p
Excessive daytime
sleepiness (pESS > 10) *
Age 1.0 1.0 1.1 0.14
BMI 1.0 1.0 1.1 0.08




0.1 0.1 0.2 <0.0001
Witnessed apnoeas—often/frequently




Age 1.0 0.9 1.0 <0.0001
BMI 1.1 1.1 1.1 <0.0001
Epilepsy 0.2 0.1 0.5 <0.0001
Category R medication 0.6 0.4 0.9 0.01
Table 6. Determinants of behavioural and emotional disturbances as assessed by generalised linear modelling (β) for
continuous variables. DBC-A Disruptive subscale analysed separately for males and females due to significant difference in
scores at baseline.
Variable Total Included Determinants Remaining in Model Estimate (β) 95% CI Lower 95% CI Upper p
DBC-A
Disruptive—Male
Category N medication 3.0 1.2 4.8 0.001
Snoring—rarely/sometimes (1–2 nights/week) −1.8 −3.4 −0.1 0.04
Snoring—often/frequently (≥3 nights/week) −1.4 −3.3 0.6 0.16
Witnessed apnoeas—rarely/sometimes
(1–2 nights/week) 2.0 0.3 3.7 0.02
Witnessed apnoeas—often/frequently
(≥3 nights/week) 1.5 −0.5 3.5 0.14
Nocturnal choking—rarely/sometimes
(1–2 nights/week) 1.4 −2.1 3.0 0.09
Nocturnal choking—often/frequently
(≥3 nights/week) −0.4 −3.2 2.4 0.77
Frequent awakenings—rarely/sometimes
(1–2 nights/week) 1.8 0.3 3.3 0.02
Frequent awakenings—often/frequently
(≥3 nights/week) 3.7 1.7 5.7 <0.0001
Unrefreshing sleep—rarely/sometimes
(1–2 nights/week) −0.1 −1.7 1.4 0.85
Unrefreshing sleep—often/frequently
(≥3 nights/week) 2.1 −0.2 4.3 0.07
DBC-A
Disruptive—Female
Category N medication 4.1 2.6 5.6 <0.0001
Snoring—rarely/sometimes (1–2 nights/week) 0.6 −1.0 2.2 0.47
Snoring—often/frequently (≥3 nights/week) 0.5 −1.2 2.3 0.54
Witnessed apnoeas—rarely/sometimes
(1–2 nights/week) −1.6 −3.1 −0.1 0.04
Witnessed apnoeas—often/frequently
(≥3 nights/week) −0.8 −3.2 1.5 0.48
Nocturnal choking—rarely/sometimes
(1–2 nights/week) 2.6 1.1 4.1 0.00
Nocturnal choking—often/frequently
(≥3 nights/week) 3.9 1.0 6.7 0.01
Frequent awakenings—rarely/sometimes
(1–2 nights/week) 1.4 −0.1 2.9 0.08
Frequent awakenings—often/frequently
(≥3 nights/week) −0.2 −2.1 1.7 0.85
Unrefreshing sleep—rarely/sometimes
(1–2 nights/week) 1.5 0.0 3.0 0.06
Unrefreshing sleep—often/frequently
(≥3 nights/week) 6.2 4.3 8.1 <0.0001
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Table 6. Cont.
Variable Total Included Determinants Remaining in Model Estimate (β) 95% CI Lower 95% CI Upper p
DBC-A
Anxiety/Antisocial
Category R medication 0.3 0.0 0.6 0.09
Category N medication 0.1 −0.2 0.4 0.56
Snoring—rarely/sometimes (1–2 nights/week) 0.0 −0.4 0.3 0.82
Snoring—often/frequently (≥3 nights/week) −0.3 −0.7 0.1 0.13
Witnessed apnoeas—rarely/sometimes
(1–2 nights/week) 0.2 −0.2 0.5 0.32
Witnessed apnoeas—often/frequently
(≥3 nights/week) −0.1 −0.5 0.3 0.67
Nocturnal choking—rarely/sometimes
(1–2 nights/week) 0.3 0.0 0.7 0.03
Nocturnal choking—often/frequently
(≥3 nights/week) 0.5 −0.1 1.1 0.11
Frequent awakenings—rarely/sometimes
(1–2 nights/week) 0.1 −0.2 0.4 0.55
Frequent awakenings—often/frequently
(≥3 nights/week) 0.0 −0.4 0.4 0.87
Unrefreshing sleep—rarely/sometimes
(1–2 nights/week) 0.0 −0.3 0.3 1.00
Unrefreshing sleep—often/frequently
(≥3 nights/week) 0.5 0.1 1.0 0.03
Daytime sleepiness—rarely/sometimes
(1–2 nights/week) 0.2 −0.1 0.5 0.20
Daytime sleepiness—often/frequently
(≥3 nights/week) 0.5 0.1 0.9 0.01
DBC-A Depressive
Category R medication 0.0 −0.7 0.7 1.00
Category N medication 2.3 1.6 3.0 <0.0001
Snoring—rarely/sometimes (1–2 nights/week) −0.2 −0.9 0.5 0.50
Snoring—often/frequently (≥3 nights/week) −0.2 −1.0 0.5 0.55
Witnessed apnoeas—rarely/sometimes
(1–2 nights/week) 0.4 −0.3 1.1 0.22
Witnessed apnoeas—often/frequently
(≥3 nights/week) 0.9 0.0 1.8 0.06
Nocturnal choking—rarely/sometimes
(1–2 nights/week) 0.5 −0.2 1.1 0.16
Nocturnal choking—often/frequently
(≥3 nights/week) 0.5 −0.7 1.6 0.46
Frequent awakenings—rarely/sometimes
(1–2 nights/week) 0.5 −0.2 1.1 0.15
Frequent awakenings—often/frequently
(≥3 nights/week) 0.3 −0.6 1.1 0.52
Unrefreshing sleep—rarely/sometimes
(1–2 nights/week) 0.5 −0.2 1.1 0.19
Unrefreshing sleep—often/frequently
(≥3 nights/week) 2.3 1.4 3.3 <0.0001
Daytime sleepiness—rarely/sometimes
(1–2 nights/week) −0.1 −0.7 0.5 0.67
Daytime sleepiness—often/frequently
(≥3 nights/week) 0.5 −0.3 1.3 0.23
3.4. Home Sleep Apnoea Testing
A summary of questionnaire responders entering the objective prevalence study is
shown in Figure 2. Of the 1067 valid responders not currently receiving CPAP therapy,
277 (26%) did not wish to be contacted further. Of the 790 invitations sent, 427 responses
were received (54%), 260 of which declined to participate. Although a reason for declining
was not sought, a number of responders annotated their reply slip with a reason; common
reasons for declining participation included belief that the individual with Down syndrome
would not tolerate the equipment or cope with the study (17%), the logistics of the study or
general family circumstances making participation problematic (10%), other co-existing
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comorbidities or disabilities (7%), and a general dislike of hospitals/medical intervention
(4%). Twelve individuals (5%) declined to participate because they did not perceive
themselves to have a sleep problem. Six individuals reported that they were on CPAP or
other sleep treatments and so were ineligible for further inclusion.
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One hundred and sixty-seven individuals were willing to undergo a home sleep study.
Of these, 151 (90%) completed informed consent and were formally recruited into the study.
Of those who did not consent, nine changed their mind and declined to participate, two
could not be contacted to book an appointment and a further two had commenced CPAP
through a local clinical service since returning a reply slip. Three individuals cancelled
appointments and were not rebooked.
In total, 149 individuals underwent home sleep studies. Of the recorded studies,
15 studies (10%) did not yield valid results, with 12 studies being unscoreable or not
tolerated, and 3 studies having no data recorded or not been used and were not repeated.
Therefore, the final analysis is based on 134 adults with Down syndrome with valid home
sleep study data.
The total scored recording time averaged 488.4 ± 115.1 min (8.1 ± 2.6 h), similar to
the estimated TST at night reported subjectively via questionnaire (8.4 ± 1.2 h), and did
not differ significantly between genders. An AHI ≥ 15 or an ODI ≥10/h is considered
diagnostic of OSA; 62% met the criteria for AHI and 41% the criteria for ODI. The prob-
able OSAHS algorithms [14] were adapted, to allow direct comparison of the subjective
diagnosis of probable OSAHS with the objective diagnosis of OSAHS by substituting
snoring ≥ 3 nights/week and witnessed apnoeas with AHI ≥ 15:
1. AHI ≥ 15 plus pESS > 10/24
2. AHI ≥ 15 plus unrefreshing sleep ≥ 3 nights per week.
3. AHI ≥ 15 plus daytime sleepiness ≥ 3 nights per week.
Using these modified algorithms, 42% of participants demonstrated OSAHS on ≥1 def-
inition (versus 56% of the same group who met the criteria for probable OSAHS).
Subjective and objective measures of OSAHS were compared. Sensitivity of the
probable OSAHS algorithms (ability of the algorithms to correctly identify individuals with
objectively diagnosed OSAHS) was 79.2%, with a specificity (ability of the algorithms to
correctly identify individuals who do not have OSAHS) of 58.5%. The positive predictive
value (PPV; the likelihood of an individual to have OSAHS in the event of meeting the
criteria for probable OSAHS via the algorithms) was 58.5% and the negative predictive
value (NPV; the likelihood of an individual to be OSAHS negative in the event of obtaining
a negative result on the algorithms) was 79.2%. The likelihood ratio (how much more likely
it is that an individual who is positive for probable OSAHS via the algorithms will have an
objective diagnosis of OSAHS) was 1.9.
4. Discussion
This is the first large-scale prevalence study of OSAHS in adults with Down syndrome.
Based on self-reported symptoms [14], the prevalence of OSAHS was approximately 37%,
of whom only 38/404 (9%) had received a prior diagnosis. Using objective methods, a
similar prevalence of 42% was observed
This mean prevalence of 40% is modest in comparison with the >80% quoted in
previous prevalence studies for the Down syndrome population, though these studies were
limited by being extremely small scale [7,8]. The 40% prevalence is substantially higher
than the 2–4% prevalence reported in the general population [4]. Clearly, OSAHS is being
markedly overlooked in the clinical care of adults with Down syndrome, with only 3%
of this cohort already diagnosed with and receiving treatment for OSAHS. This may be
related to diagnostic overshadowing, leading to potentially inappropriate treatments for
behavioural and emotional disturbances which may result directly from poor sleep but are
not being recognised as such.
4.1. Acceptability of Home Sleep Apnoea Testing
Home sleep apnoea testing with the Embletta® Gold™ cardiorespiratory polygraphy
device was well-tolerated by the participants, with a success rate of 90% over two nights’
recording. This is similar to previously published data on the use of home sleep apnoea
testing equipment in the general population [18]. Home sleep apnoea testing is common-
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place clinically in the UK and Europe, offering logistical as well as financial benefits over
inpatient polysomnography [15]. People with Down syndrome may be medical-phobic or
find in-patient visits distressing, so adequate testing in the home environment to make a
diagnosis of OSAHS as accessible as possible is vital.
4.2. Use of the pESS in Down Syndrome
A discrepancy was noted between self-reporting of daytime sleepiness per se and
the percentage of those reporting elevated pESS scores. Although the pESS appears to
be a useful measure in this population, overall scores may have been reduced due to
the unsuitability of some of the questions. The question regarding sitting down and
reading may not be appropriate given the diminished literacy in this population, and may
be problematic in those with visual impairment. With regard to the question related to
afternoon napping, 69% of responders indicated via the pESS that they were likely to nap
in the afternoon should circumstances permit, despite only 28% of respondents reporting
daytime napping. This may reflect a lack of opportunity to nap (due to employment,
education or other daytime commitments) rather than absence of sleepiness. Modification
of the pESS to improve its utility in this specific population may be appropriate.
4.3. Self-Reporting of Nocturnal Symptoms
A large percentage of responders did not know whether or not they had apnoeas,
which may have resulted in underestimation of the prevalence of this symptom. This may
reflect the relative complexity of the description (people are generally more familiar with
snoring than “pauses in breathing”), but may also relate to the availability of a second
individual to witness the apnoeas; many people with Down syndrome live in supported
accommodation without a live-in caregiver or family member and, whereas snoring may
be heard outside the bedroom, apnoeas are not. This may also explain the relatively young
mean age of respondents, who may still reside at home. However, this is speculative, given
that information on living arrangements was not recorded in this study.
All responders with probable OSAHS reported snoring ≥ 3 nights per week, as this
variable was common to all three algorithms. Sleep apnoea without snoring is rare in the
literature, though one polysomnographic study in adults with Down syndrome [19] noted
snoring in only 7 of 12 participants with studies diagnostic of sleep apnoea. The algorithms
used in the current study may be under-estimating the prevalence of OSAHS by excluding
those who snored < 3 nights per week.
4.4. Behavioural and Emotional Disturbances
Generally, scores on the subscales of the DBC-A were low. A floor effect was noted
on the Anxiety/Antisocial subscale, with mean scores of 0/14 in both males and females,
regardless of sleep symptoms. There may be an element of selection bias, with families of
individuals with more severe behavioural and emotional problems less likely to respond.
However, probable OSAHS was associated with significant increases in raw and mean
scores as well as the breadth and intensity of problem behaviours across all three subscales,
supporting the hypothesis of OSAHS impacting negatively on behaviour and emotion in
adults with Down syndrome. This may lead to inappropriate prescribing of psychotropic
drugs. Given their side effects, and the difficulties that people with Down syndrome may
have in reporting side effects due to cognitive and communication impairments, this may
cause further unnecessary suffering.
Cognitive and behavioural deficits in adults and children with untreated OSAHS
are well documented in the general adult population, as is reversal of these deficits with
treatment [4]. Since adults with Down syndrome already exhibit cognitive impairment,
untreated sleep-disordered breathing may present a “double-hit” on cognition in these
individuals. It is possible that untreated sleep-disordered breathing may contribute to the
acceleration of the cognitive decline seen in early onset dementia, which is common in
adults with Down syndrome [3]; a recent review by Fernandez and Edgin [7] suggests that
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sleep disruption might lead to both earlier onset of dementia and more rapid deterioration.
However, to date, no published studies have investigated the effect of sleep-disordered
breathing on cognitive function in adults with Down syndrome, nor the effect of CPAP
therapy in this group. A recent paper by Cody et al. [20] has suggested that disrupted sleep
in adults with Down syndrome was more likely to be associated with impaired cognitive
functioning and higher striatal beta amyloid deposition.
4.5. Adenotonsillectomy
Adenotonsillectomy is the first-line treatment for OSAHS in the majority of typically
developing children, curative in 75–100%, although previous studies report less favourable
results in children with Down syndrome [21]. In our study, previous surgery did not
result in a lower rate of excessive daytime sleepiness, and those who had previously had
adenoids and/or tonsils removed were more likely to exhibit witnessed apnoeas and
trended towards reporting more Disruptive and Depressive behaviour. Whilst surgery
may result in a partial or initial improvement, results are not sustained into adulthood in
the Down syndrome population. This is supported by a previous study in a population of
adolescents and young adults (age 14–30 years) with Down syndrome [22].
4.6. Limitations of the Study
Inherent non-responder bias in questionnaire studies is well-documented, and difficult
to avoid [23]; however, we believe that the questionnaire was designed in such a way as to
minimise this. An element of selection bias may be evident, with those individuals and
families with concerns about sleep more likely to respond.
There was some regional variation in method. An England-based charity which sent
out the majority (3895; 74%) of the questionnaires in England, Wales and Northern Ireland
declined to send out a second questionnaire to individuals who did not respond initially. A
repeat mailout was conducted by all other services involved in the study. This may have
contributed to the reduced response rate in these countries.
Although the questionnaire was designed to be completed by the individual with
Down syndrome, it is likely that a large proportion of the questionnaires were completed by
a proxy on the participant’s behalf. A “proxy effect” has been reported in the literature [24].
However, since this more often results in under-reporting of characteristics, it is likely that
our estimates of prevalence, sleepiness and behaviour are conservative. The approach
we utilized in determining a positive or negative diagnosis of OSAHS appeared to be
reasonable, but diagnosis by questionnaire and self-report is always fraught with bias,
and objective measurement of sleep disordered breathing is always preferable. In the
future, better questionnaire methods may be devised that are more specific to the Down
syndrome group.
The majority of participants were identified through patient support groups, and so
may not be representative of the Down syndrome population as a whole. Older adults may
be under-represented, possibly due to inability to complete the questionnaire on account of
comorbidities such as dementia, or absence of a living relative or family member to assist
with completion.
One final comment regarding the validity of our results pertains to non-responders.
At the time of our study, we did not have the facility to sample non-responders with respect
to symptoms of sleep disordered breathing in order to assess whether the prevalence was
equally high—a bias which should be controlled for in future studies.
Information on ethnicity was not collected, and our prevalence data may not be
transferable to other countries with divergent ethnicity. However, work comparing the
prevalence of OSAHS in adults with Down syndrome in Scotland with that in Japan
showed similar prevalence of symptoms, despite the ethnic and anthropometric differences
between these two populations [25].
This study focussed only on symptoms of OSAHS. However, several symptoms such
as excessive daytime somnolence, unrefreshing sleep and frequent night wakening are
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common to other sleep disorders, which cannot be ruled out as co-morbid or alternative
causes for these symptoms. Questionnaire assessment of any disorder, including OSAHS,
generally results in a lower specificity than sensitivity and we advocate testing all patients
where there is any suspicion of sleep-disordered breathing to ensure it is not missed.
Building on this work, objective sleep study data could further quantify the severity
of sleep-disordered breathing in adults with Down syndrome. The reliability of home sleep
apnoea testing is now validated for the diagnosis of sleep disordered breathing in adults
in comparison to polysomnography [15]. However, it should be noted that there is, in
general, a difference of about 20% between home testing and in-lab PSG with respect to
the apnoea–hypopnoea index [26]. Although patients with OSAHS and Down syndrome
should be offered treatment with continuous positive airway pressure therapy, a strong
evidence base for this was lacking at the time our study was conceived of and commenced
(2010–2011).
5. Conclusions
In conclusion, this first large-scale study of OSAHS prevalence in adults with Down
syndrome shows an estimate of 37%—nearly 9 times higher than in the general adult pop-
ulation. Unfortunately, neither assessment nor treatment of OSAHS in adults with Down
syndrome appears to be common clinical practice, as evidenced by only 7% of the study
population having a prior diagnosis of OSA and 3.4% receiving CPAP treatment, despite
the potential benefits for improved cognitive function, health and wellbeing. This study
strengthens the evidence for guidelines for the monitoring of OSAHS in Down syndrome
adults and the establishment of specialised clinics for adults with Down syndrome and
other forms of intellectual disabilities. We argue for improved access to these services and
measures to improve awareness of this disorder amongst people with Down syndrome,
their families and all professionals involved in their care.
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